Metabolic · 9 min
Compounded tirzepatide: brand, compounded and research-grade
Written by Aaron CuhaReviewed 27 Sep 2026
Compounded tirzepatide is not FDA-approved, and FDA does not check pharmacy-made copies for safety, whether they work, or quality before they are sold. The shortage that let pharmacies make copies ended in late 2024, and their deadlines to stop ran out in March 2025. The studies were done on the brand-name drug, Mounjaro and Zepbound.
FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of 1 Sep 2026)
Brand, pharmacy copies and research vials, side by side
| Product | FDA-approved? | Who checks quality | Studies in people |
|---|---|---|---|
| Brand-name (Mounjaro, Zepbound) | Yes, FDA-approved. | Made to the manufacturing standards reviewed for approval. | 9 finished studies and 22,802 people, on this site's tirzepatide page. |
| Copy made by a local compounding pharmacy | No. FDA does not check pharmacy-made copies for safety, whether they work, or quality before they are sold. | Checked mainly by state pharmacy boards, not held to drug-factory rules. Must be for one patient with a prescription, and routinely copying an approved drug is not allowed. | None of its own. The studies were of the brand-name drug. |
| Copy made by a large compounding facility | No. | Inspected by FDA and held to drug-factory rules. Can only make tirzepatide from raw powder if FDA lists it as needed or in short supply, and FDA said in April 2026 it was neither. | None of its own. |
| “Research use only” | No. FDA calls these illegally sold unapproved drugs. | FDA says nobody knows what is in them, and they are sold to the public with dosing instructions. | None. |
What changed, and when
15 Dec 2022
FDA says tirzepatide is in short supply, which lets pharmacies make their own copies.
FDA, Resolution of Tirzepatide Injection Product Shortage (memo, 19 Dec 2024)
2 Oct 2024
FDA says the shortage is over. A lawsuit sends the decision back to FDA for a second look.
FDA, Resolution of Tirzepatide Injection Product Shortage (memo, 19 Dec 2024)
19 Dec 2024
FDA confirms the shortage is over and gives pharmacies deadlines to stop making copies.
FDA, Resolution of Tirzepatide Injection Product Shortage (memo, 19 Dec 2024)
18 Feb 2025
Deadline for local compounding pharmacies. It was pushed back until a court ruled on 5 Mar 2025 against the pharmacies, and FDA said the deadline had passed.
19 Mar 2025
Deadline for large compounding facilities.
6 Feb 2026
FDA says it will crack down on mass-marketed copies of GLP-1 drugs, naming Hims & Hers.
FDA statement, FDA Intends to Take Action Against Non-FDA-Approved GLP-1 Drugs (6 Feb 2026)
3 Mar 2026
FDA warns 30 online telehealth companies about how they advertise copied GLP-1 drugs.
FDA, FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s (3 Mar 2026)
31 Mar 2026
FDA tells a seller its tirzepatide labeled “for research” was really being sold for people to use.
30 Apr 2026
FDA proposes that large compounding facilities may no longer make tirzepatide, semaglutide or liraglutide from raw powder.
30 Jul 2026
Last day for public comments on that proposal. No final decision had been published as of 27 Sep 2026.
Federal Register 2026-12937, comment period extended to 30 Jul 2026 (26 Jun 2026)
Problems FDA has seen
By 31 May 2026, FDA had received more than 730 reports of people having problems after using pharmacy-made tirzepatide, and 990 for pharmacy-made semaglutide. FDA says the real numbers are likely higher, because local pharmacies don't have to report problems. A report doesn't prove the drug caused the problem.
Some reports involve people given higher doses than the brand-name label allows. FDA has also found vials labeled with the names of pharmacies that don't exist. For pharmacy-made GLP-1 vials meant for several doses, FDA says to throw the vial away 28 days after first use, even if some is left.
FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of 1 Sep 2026)
Added vitamins, other versions and imports
Added ingredients. Adding something like vitamin B12 doesn't stop a pharmacy product from counting as a copy of the brand-name drug, FDA says. FDA's example was semaglutide, not tirzepatide.
Other chemical versions. FDA has said some semaglutide versions used by pharmacies are a different chemical from the brand-name drug. For tirzepatide, FDA has only raised the concern in general terms and has not named a specific version.
FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of 1 Sep 2026) FDA, FDA Launches Green List to Protect Americans from Illegal Imported GLP-1 Drug Ingredients (5 Sep 2025)
Imports. FDA tries to stop poor-quality GLP-1 ingredients from entering the US. Separately, after a complaint by Eli Lilly, a US trade body ruled in 2025 that tirzepatide products that copy Lilly's brand or lie about where they come from can't be imported.
FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of 1 Sep 2026) Federal Register 2025-06352, US International Trade Commission, Inv. 337-TA-1377 (15 Apr 2025)
“Research use only” labels don't change the rules
FDA has warned companies selling tirzepatide and other GLP-1 drugs labeled “for research” or “not for human use” while selling them to the public with dosing instructions. In a March 2026 letter, FDA told one seller that its “research” tirzepatide was plainly meant for people.
FDA, FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss (current as of 1 Sep 2026) FDA warning letter, Mile High Compounds LLC (31 Mar 2026)
What this page does not say
It gives no dose and no recommendation. It doesn't say any pharmacy copy or research vial is unsafe, and it doesn't say any is safe, because FDA has checked none of them. Rules change, and the dates above are as of 27 September 2026. Talk to a prescriber about whether any of these is right for you.
Related
Educational use only. This database summarizes published research and is not medical advice. Where a dose appears it is a record of what a trial or clinic ran, or what people describe doing, with its source attached. Nothing here is a recommendation for personal use.